NCT05559879 2026-04-15
Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma
University of Alabama at Birmingham
Phase 1/2 Recruiting
Clinical Trials
4 trialsNCT06405230 2026-02-03
Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Extracellular Vesicles (EVs), Patient-derived Organoid (PDOs)s and Immune-marker Positron Emission Tomography (PET) Scanning in Non-small Cell Lung Cancer (NSCLC)
GlaxoSmithKline
Phase 1/2 Recruiting
NCT06796907 2025-10-14
BEHOLD-2
GlaxoSmithKline
Phase 1/2 Recruiting
NCT05784012 2025-03-13
RADIAN
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
Phase 1/2 Recruiting